Cancer recurrence monitoring through genetic testing provides an early warning system for detecting cancer cells that may return after treatment. This proactive approach helps guide treatment decisions and improve long-term outcomes by catching recurrence early.
Genetic testing for recurrence involves analysing blood or tissue samples for specific cancer markers that could indicate the cancer’s return. By tracking these markers, doctors can detect recurrence at a molecular level before it becomes clinically visible, allowing for prompt treatment.
Together, these data layers fuel the RGCC Onconomics Plus, Oncotrace, and Immune Frame panels, turning test results into personalised action plans.
Cancer recurrence monitoring allows for timely interventions when genetic markers suggest a relapse. By detecting recurrence early, it increases the chances of successful treatment and long-term remission, improving survival rates.
Early Detection: Catch recurrence at the genetic level before physical symptoms appear.
Proactive Management: Monitor for recurrence with regular testing and adjust treatment as needed.
Improved Outcomes: Early detection allows for targeted interventions, improving survival chances.
Schedule a consultation to discuss your cancer recurrence monitoring options.
Meet with our specialists to understand the role of genetic testing in recurrence monitoring.
A blood or tissue sample will be collected to track cancer markers.
Regular tests will help you stay on top of potential recurrence, guiding ongoing treatment.
Cancer recurrence monitoring uses advanced genetic tests to detect the return of cancer at a molecular level. By identifying specific genetic markers in blood or tumour tissue, doctors can spot early signs of relapse, often before symptoms appear or imaging shows changes.
This form of monitoring is applicable to a wide range of cancers, including solid tumours and blood cancers. Your healthcare provider will determine the appropriate genetic markers to track based on your original cancer type and treatment history.
The test involves a simple blood draw or tumour biopsy (usually 5–10 ml). The sample is analysed for molecular markers known to be associated with cancer recurrence. It’s non-invasive and can be repeated at regular intervals for ongoing surveillance.
Monitoring typically starts after your initial treatment is completed and you’ve entered remission. Regular follow-up tests can then be scheduled to track for any early signs of relapse, tailored to your risk level and type of cancer.
Catching recurrence early means treatment can start sooner, often with more targeted and less aggressive approaches. This significantly improves your chances of achieving a second remission and long-term survival.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.